Stay updated on Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial
Sign up to get notified when there's something new on the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page.

Latest updates to the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page
- Check3 days agoChange DetectedNew study sites were added (Columbus, OH; Rabin Medical Center in Israel; Hospital Universitario Vall de Hebron in Spain) and some existing site identifiers were updated.SummaryDifference0.6%

- Check10 days agoChange DetectedRevision updated to v3.5.0 and the previous revision v3.4.3 was removed.SummaryDifference0.0%

- Check17 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a general site version update with no visible changes to study content or navigation.SummaryDifference0.0%

- Check24 days agoNo Change Detected
- Check46 days agoChange DetectedRevision updated to v3.4.2; the funding-lapse notice and the prior revision notice (v3.4.1) were removed.SummaryDifference0.4%

- Check53 days agoChange DetectedA site-wide funding notice was added and the site version updated to v3.4.1, replacing the previous revision v3.4.0.SummaryDifference0.4%

- Check60 days agoChange DetectedNo core content changes; minor UI/metadata text updates were made, including Show glossary, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page.